{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:44:11Z","timestamp":1788572651093,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1053\/j.seminhematol.2025.04.006","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T19:12:23Z","timestamp":1746213143000},"page":"76-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0840-3499","authenticated-orcid":false,"given":"Shirley","family":"D'Sa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahanzaib","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signy","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dogliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindriska","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Leiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Varettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M.I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Lunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.04.006_bib0001","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1200\/jco.2010.28.15_suppl.8114","article-title":"Clinical characteristics and treatment outcome of disease-related peripheral neuropathy in Waldenstrom's macroglobulinemia (WM)","volume":"28","author":"Treon","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0002","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2023-180673","article-title":"Prevalence of peripheral neuropathy (PN) among patients with asymptomatic monoclonal gammopathies: a clinical & electrophysiological study","volume":"142","author":"Zis","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0003","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/WNL.37.9.1506","article-title":"Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins","volume":"37","author":"Nobile-Orazio","year":"1987","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.2830450105","article-title":"Peripheral neuropathy in IgM monoclonal gammopathy and W\u00e4ldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component","volume":"45","author":"Baldini","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0006","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1212\/WNL.0000000000207665","article-title":"Age-related changes in neurologic examination and sensory nerve amplitude in the general population: aging of the peripheral nervous system","volume":"101","author":"Taams","year":"2023","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0007","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1212\/WNL.0000000000003293","article-title":"Prevalence of polyneuropathy in the general middle-aged and elderly population","volume":"87","author":"Hanewinckel","year":"2016","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0008","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1212\/WNL.37.2.242","article-title":"Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein","volume":"37","author":"Hays","year":"1987","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-5728(88)90019-7","article-title":"Antibodies to sulfated glucuronic acid containing glycosphingolipids in neuropathy associated with anti-MAG antibodies and in normal subjects","volume":"17","author":"McGinnis","year":"1988","journal-title":"J Neuroimmunol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/mus.880111111","article-title":"Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies","volume":"11","author":"Willison","year":"1988","journal-title":"Muscle Nerve"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00294225","article-title":"Morphological changes in IgM paraproteinaemic neuropathy","volume":"80","author":"Jacobs","year":"1990","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0012","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00005072-199501000-00012","article-title":"Experimental induction of myelin changes by anti-MAG antibodies and terminal complement complex","volume":"54","author":"Monaco","year":"1995","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0013","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.33.7.939","article-title":"Anti-MAG IgM antibodies in patients with neuropathy and IgM M proteins: detection by ELISA","volume":"33","author":"Nobile-Orazio","year":"1983","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210000","article-title":"Optimizing anti-myelin-associated glycoprotein and IgM-gammopathy testing for neuropathy treatment evaluation","volume":"103","author":"Klein","year":"2024","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-4598(200001)23:1<73::AID-MUS9>3.0.CO;2-5","article-title":"Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy","volume":"23","author":"Notermans","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0017","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0018","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10072-019-04089-7","article-title":"Anti-MAG IgM: differences in antibody tests and correlation with clinical findings","volume":"41","author":"Mat\u00e0","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/jns.12682","article-title":"Distinguishing chronic inflammatory demyelinating polyneuropathy from mimic disorders: the role of statistical modeling","volume":"30","author":"Swart","year":"2025","journal-title":"J Peripher Nerv Syst"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0020","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.3324\/haematol.2022.280953","article-title":"IgM monoclonal gammopathies of clinical significance: diagnosis and management","volume":"107","author":"Khwaja","year":"2022","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0021","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0b013e3181ccc6b9","article-title":"Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study","volume":"74","author":"Niermeijer","year":"2010","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0022","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0022-510X(99)00049-0","article-title":"Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance","volume":"164","author":"Di Troia","year":"1999","journal-title":"J Neurol Sci"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0023","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ana.410180203","article-title":"Immunofluorescence study of patients with neuropathy and IgM M proteins","volume":"18","author":"Takatsu","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0024","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/(SICI)1097-4598(199908)22:8<1030::AID-MUS4>3.0.CO;2-H","article-title":"Anti-MAG IgM penetration into myelinated fibers correlates with the extent of myelin widening","volume":"22","author":"Ritz","year":"1999","journal-title":"Muscle Nerve"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s004010050835","article-title":"Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy","volume":"95","author":"Gabriel","year":"1998","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0026","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/00207454.2016.1191013","article-title":"Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies","volume":"127","author":"Galassi","year":"2017","journal-title":"Int J Neurosci"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0027","first-page":"1","article-title":"Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials","volume":"82","author":"Latov","year":"2024","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0028","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/ene.15553","article-title":"Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: clinical, hematological and neurophysiological correlations during 2\u2009years of follow-up","volume":"29","author":"Parisi","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0029","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"10","author":"Lunn","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jns.12156","article-title":"Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study","volume":"21","author":"Ferfoglia","year":"2016","journal-title":"J Peripher Nerv Syst"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0031","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: b-cell depletion chemotherapy using Rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0032","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14786410500441664","article-title":"Rituximab therapy in monoclonal IgM-related neuropathies","volume":"47","author":"Kilidireas","year":"2006","journal-title":"Leuk lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.006_bib0033","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1529-8027.2007.00129.x","article-title":"Predictors of response to rituximab in patients with neuropathy and anti-myelin-associated glycoprotein immunoglobulin M","volume":"12","author":"Benedetti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.04.006_bib0034","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1212\/01.wnl.0000335268.70325.33","article-title":"Long-term effect of rituximab in anti-MAG polyneuropathy","volume":"71","author":"Benedetti","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.006_bib0035","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.04.006_bib0036","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1529-8027.2011.00343.x","article-title":"Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy","volume":"16","author":"Gruson","year":"2011","journal-title":"J Peripher Nerv Syst"},{"issue":"24","key":"10.1053\/j.seminhematol.2025.04.006_bib0037","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"L\u00e9ger","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.006_bib0038","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.3324\/haematol.2013.087213","article-title":"Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients","volume":"98","author":"Hospital","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.04.006_bib0039","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2013-306958","article-title":"Fc\u03b3 receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy","volume":"85","author":"Stork","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.006_bib0040","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/jnnp-2017-315736","article-title":"IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy","volume":"88","author":"Campagnolo","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116777","article-title":"Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy","volume":"413","author":"Massa","year":"2020","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.04.006_bib0042","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3324\/haematol.2019.243139","article-title":"Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes","volume":"106","author":"Colchester","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.006_bib0043","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/bloodadvances.2024014115","article-title":"Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr\u00c3\u00b6m macroglobulinemia","volume":"9","author":"Heyman","year":"2024","journal-title":"Blood Advances"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.006_bib0044","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle & Nerve"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.04.006_bib0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/01.wnl.0000201193.00382.b3","article-title":"High-dose rituximab and anti-MAG-associated polyneuropathy","volume":"66","author":"Renaud","year":"2006","journal-title":"Neurology"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0046","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2014.07.055","article-title":"Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy","volume":"345","author":"Sala","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0047","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1200\/JCO.2005.04.6474","article-title":"Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia","volume":"24","author":"Noronha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.04.006_bib0048","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/brainsci14121294","article-title":"IgM flare in anti-MAG neuropathy post rituximab treatment: A clinical case and a systematic review of the literature","volume":"14","author":"Siconolfi","year":"2024","journal-title":"Brain Sciences"},{"issue":"6 Suppl","key":"10.1053\/j.seminhematol.2025.04.006_bib0049","first-page":"ECR17","article-title":"Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-MAG neuropathy after treatment with rituximab","volume":"91","author":"Gironi","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/mus.20386","article-title":"Worsening after rituximab treatment in anti-mag neuropathy","volume":"32","author":"Broglio","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0051","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200122","article-title":"Mutational profile in 75 patients with anti-myelin-associated glycoprotein neuropathy: clinical and hematologic therapy response and hints on new therapeutic targets","volume":"10","author":"Castellani","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577127","article-title":"Association of variability in antibody binding affinity with a clinical course of anti-MAG neuropathy","volume":"339","author":"Matsui","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"Pt 4","key":"10.1053\/j.seminhematol.2025.04.006_bib0053","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","article-title":"Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies","volume":"123","author":"Nobile-Orazio","year":"2000","journal-title":"Brain"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0054","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0055","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0056","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.21.00105","article-title":"Combining Ixazomib with subcutaneous Rituximab and Dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia: final analysis of the phase I\/II HOVON124\/ECWM-R2 study","volume":"40","author":"Kersten","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0057","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.006_bib0058","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0059","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10928","article-title":"Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib","volume":"8","author":"Yasuda","year":"2022","journal-title":"Heliyon"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.04.006_bib0061","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001181","article-title":"The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies","volume":"9","author":"Briani","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0062","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"Comi","year":"2002","journal-title":"J Neurol"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.04.006_bib0063","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.seminhematol.2023.03.002","article-title":"Report of Consensus Panel 6 from the 11 th International Workshop on Waldenstr\u00f6m's Macroglobulinemia on Management of Waldenstr\u00f6m's macroglobulinemia related amyloidosis","volume":"60","author":"Merlini","year":"2023","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0064","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s004010050785","article-title":"Blood-nerve barrier in IgM paraproteinemic neuropathy: a clinicopathologic assessment","volume":"95","author":"Kanda","year":"1998","journal-title":"Acta Neuropathol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/WCO.0000000000000975","article-title":"Antibody testing in neuropathy associated with anti-myelin-associated glycoprotein antibodies: where we are after 40 years","volume":"34","author":"Latov","year":"2021","journal-title":"Curr Opin Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0066","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/450391","article-title":"Heterogeneity of polyneuropathy associated with anti-MAG antibodies","volume":"2015","author":"Magy","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577288","article-title":"Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy","volume":"345","author":"Liberatore","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0068","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ana.410260408","article-title":"Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia","volume":"26","author":"Nobile-Orazio","year":"1989","journal-title":"Ann Neurol"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0069","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies","volume":"136","author":"Le Cann","year":"2020","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.04.006_bib0070","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/jnnp-2023-332443","article-title":"Excellent response to anti-CD38 therapy with daratumumab in a patient with severe refractory CANOMAD","volume":"95","author":"Pascual-Go\u00f1i","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:22:59Z","timestamp":1750843379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0037196325000162"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}